The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Celcuity, the Plymouth-based clinical-stage biotechnology company, has been the best-performing Minnesota stock of the summer and has outperformed all the S&P 500 stocks, including the tech giants ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMXT 1501 in combination with ...

Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will ...

Researchers have introduced a molecular switch that could control when drugs are active or inactive in the body.

Since the reform of China's drug review and approval in 2015, it has successfully stimulated the enthusiasm of domestic pharmaceutical companies to carry out innovative drug research and development, ...

SciTech Development Inc., a clinical-stage oncology company in Detroit, has closed its Convertible Note Round No. 3 (CNR 3) ...

Scientists at Université de Montreal and its Institute for Research in Immunology and Cancer have begun a phase-1 clinical ...

Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...